QSAM Biosciences, Inc. – OTC:QSAM

Add to watchlist

$4.95

-3.35

-40.36%

Market closed

Open in 3 days

+12.16%

month

+55.14%

quarter

+38.91%

year

Market Cap	7.97M
Enterprise value	7.27M

P/E	-1.19
EV/Sales	N/A
EV/EBITDA	-0.85
Price/Sales	N/A
Price/Book	-3.63
PEG ratio	-0.01
EPS	-1.79

Revenue	N/A
EBITDA	-3.94M
Income	-4.98M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

QSAM Biosciences, Inc. (OTC:QSAM): Profit margin
Mar 2023	0	-2.09M
Jun 2023	0	-1.23M
Sep 2023	0	-1.16M
Dec 2023	0	-483.91K

QSAM Biosciences, Inc. (OTC:QSAM): Debt to assets
Mar 2023	1290305	1.29M	100.53%
Jun 2023	462612	1.37M	297.85%
Sep 2023	610317	1.71M	280.26%
Dec 2023	1705247	1.03M	60.57%

QSAM Biosciences, Inc. (OTC:QSAM): Cash Flow
Mar 2023	-440.46K	1.06M
Jun 2023	-804.37K	342.66K
Sep 2023	-443.09K	500K
Dec 2023	-1.16M	2.1M

QSAM Biosciences alternative data

QSAM Biosciences, Inc. (OTC:QSAM): Employee count
Aug 2023	4
Sep 2023	4
Oct 2023	4
Nov 2023	4
Dec 2023	4
Jan 2024	4
Feb 2024	4
Mar 2024	4
Apr 2024	4
May 2024	4
Jun 2024	4
Jul 2024	4

QSAM Biosciences
Insider Trading

QSAM Biosciences, Inc. (OTC:QSAM): Insider trades (number of shares)
Period	Buy	Sel
Jan 2021	23	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	22 Jan 2021	BAUM DOUGLAS R director, officer: CEO & Director director, officer: CEO & Director	Series B Preferred Stock	3	$3,000	$9,000
Purchase	22 Jan 2021	NELSON CHRISTOPHER M. director, officer: General Counsel a.. director, officer: General Coun..	Preferred Series B Stock	20	$20,000	$400,000
Purchase	1 Jun 2018	MAYERSOHN JOEL DAVID director director	options to purchase common stock	400,000	$0.1	$40,000
Purchase	1 Jun 2018	PEITZ TRISTAN director director	options to purchase common stock	400,000	$0.1	$40,000
Purchase	31 Mar 2017	PIMPUTKAR SUDHEER officer: Chief Technology Officer officer: Chief Technology Officer	common stock	372,923	$0.15	$55,938
Purchase	31 Mar 2017	NELSON CHRISTOPHER M. director, officer: CEO director, officer: CEO	common stock	666,667	$0.15	$100,000
Purchase	31 Mar 2017	MURCIA MICHELLE officer: CFO officer: CFO	common stock	52,000	$0.15	$7,800
Purchase	27 Feb 2017	BOLIN KEVIN director director	common stock	10,000,000	$0.02	$200,000
Purchase	27 Feb 2017	NELSON CHRISTOPHER M. director, officer: CEO director, officer: CEO	Common Stock	5,000,000	$0.02	$100,000
Purchase	28 Dec 2016	MAYERSOHN JOEL DAVID director director	options to purchase common stock	200,000	$0.21	$42,000

QSAM insider trading transactions

QSAM Biosciences
Latest News

Tuesday, 16 April 2024
08:30	QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER	globenewswire.com
Wednesday, 7 February 2024
16:43	Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform	globenewswire.com
16:00	QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals	globenewswire.com
Tuesday, 14 November 2023
07:30	QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee	globenewswire.com
Monday, 13 November 2023
17:30	Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®	prnewswire.com
Wednesday, 16 August 2023
08:00	QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data	globenewswire.com
Monday, 23 January 2023
08:30	QSAM Biosciences to Present at the Emerging Growth Conference on Wednesday, January 25, 2023	GlobeNewsWire

Frequently Asked Questions (FAQ)

What's the price of QSAM Biosciences stock today?

One share of QSAM Biosciences stock can currently be purchased for approximately $4.95.
When is QSAM Biosciences's next earnings date?

Unfortunately, QSAM Biosciences's (QSAM) next earnings date is currently unknown.
Does QSAM Biosciences pay dividends?

No, QSAM Biosciences does not pay dividends.
How much money does QSAM Biosciences make?

QSAM Biosciences has a market capitalization of 7.97M.
What is QSAM Biosciences's stock symbol?

QSAM Biosciences, Inc. is traded on the OTC under the ticker symbol "QSAM".
What is QSAM Biosciences's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of QSAM Biosciences?

Shares of QSAM Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does QSAM Biosciences have?

As Jul 2024, QSAM Biosciences employs 4 workers.
When QSAM Biosciences went public?

QSAM Biosciences, Inc. is publicly traded company for more then 4 years since IPO on 24 Dec 2020.
What is QSAM Biosciences's official website?

The official website for QSAM Biosciences is qsambio.com.
Where are QSAM Biosciences's headquarters?

QSAM Biosciences is headquartered at 9442 Capital of Texas Hwy N, Austin, TX.
How can i contact QSAM Biosciences?

QSAM Biosciences's mailing address is 9442 Capital of Texas Hwy N, Austin, TX and company can be reached via phone at +51 23434558.

QSAM Biosciences, Inc.

qsambio.com

Exchange:

OTC

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer and related diseases. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was incorporated in 2004 and is headquartered in Austin, Texas.

+51 23434558

9442 Capital of Texas Hwy N
Austin, TX 78759

CIK: 0001310527
ISIN: US74738N1037
CUSIP: 74738N103